StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)

Stock analysts at StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report issued on Friday. The brokerage set a “hold” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Can-Fite BioPharma in a report on Thursday, May 9th.

Can-Fite BioPharma Price Performance

CANF opened at $2.47 on Friday. Can-Fite BioPharma has a fifty-two week low of $1.81 and a fifty-two week high of $3.33. The firm has a market capitalization of $8.74 million, a price-to-earnings ratio of -1.38 and a beta of 1.58. The company’s 50 day moving average price is $2.17 and its two-hundred day moving average price is $2.12.

Can-Fite BioPharma (NYSE:CANF) last posted its earnings results on Thursday, March 28th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). Can-Fite BioPharma had a negative return on equity of 113.75% and a negative net margin of 1,027.46%. The business had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.20 million. As a group, equities research analysts predict that Can-Fite BioPharma will post -0.03 EPS for the current year.

Institutional Investors Weigh In On Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. Armistice Capital LLC acquired a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 154,363 shares of the company’s stock, valued at approximately $340,000. Armistice Capital LLC owned about 4.36% of Can-Fite BioPharma as of its most recent filing with the SEC. 21.00% of the stock is currently owned by institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.